Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 | DelveInsight

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, technological advancements, widespread smartphone usage, and a growing awareness of digital health solutions. These factors are expected to fuel strong demand for smart inhalers from 2025 to 2032.

New York, USA, May 29, 2025 (GLOBE NEWSWIRE) — Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 | DelveInsight

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, technological advancements, widespread smartphone usage, and a growing awareness of digital health solutions. These factors are expected to fuel strong demand for smart inhalers from 2025 to 2032.

DelveInsight’s Smart Inhalers Market Insights report provides the current and forecast market analysis, individual leading smart inhalers companies’ market shares, challenges, smart inhalers market drivers, barriers, trends, and key market smart inhalers companies in the market.

Key Takeaways from the Smart Inhalers Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global smart inhalers market during the forecast period. 
• In the product type segment of smart inhalers, the MDI category had a significant revenue share in the year 2024.
• Notable smart inhaler companies such as Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline plc, AptarGroup, Inc., Novartis AG, OPKO Health, Inc., BreatheSuite Inc., adherium, Propeller Health, H&T Presspart Manufacturing Ltd, Zeolr Technologies Pvt Ltd, Findair Sp. z o. o, Lupin, Personal Air Quality Systems Pvt Ltd (PAQS), Biocorp, Cognita Labs, and several others are currently operating in the smart inhalers market.
• In October 2024, Modivcare Inc., a top provider of technology-enabled healthcare services offering integrated supportive care solutions, announced a partnership through its subsidiaries Valued Relationships, Inc. (VRI) and Higi Care, LLC with Tenovi, a leader in cellular-connected remote monitoring technology. Together, they will deliver Adherium’s Hailie® Smart inhalers to improve care for patients with chronic respiratory conditions.
• In June 2024, Aseptika introduced the PUFFClicker3, a universal smart inhaler dose tracker designed to work with both pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs).

To read more about the latest highlights related to the smart inhalers market, get a snapshot of the key highlights entailed in the Global Smart Inhalers Market Report

Smart Inhalers Overview

Smart inhalers are innovative devices designed to improve the management of respiratory conditions like asthma and COPD. These inhalers are equipped with sensors and Bluetooth connectivity, allowing them to track usage patterns and ensure patients are taking their medications correctly. By connecting to a smartphone app, smart inhalers can provide real-time data on medication adherence, timing, and dosage, which helps patients and healthcare providers monitor treatment progress. Additionally, they can send reminders to patients to ensure timely medication use, offering personalized insights that can lead to better disease management and improved outcomes.

The data collected by smart inhalers can also contribute to more effective care through remote monitoring by healthcare professionals. This can lead to early intervention if a patient’s condition worsens or if medication use is irregular, reducing hospital visits and emergencies. Smart inhalers not only offer a more tailored approach to treatment but also enhance the overall patient experience by making it easier to manage complex respiratory diseases. With continuous advancements in technology, these devices have the potential to transform chronic respiratory care by fostering more efficient and personalized healthcare delivery.

Smart Inhalers Market Insights

North America led the smart inhalers market in 2024, and it is predicted to maintain its dominance throughout the forecast period from 2025 to 2032. This leadership is primarily attributed to the growing incidence of chronic respiratory conditions and the demand for more effective management solutions. The region’s market growth will be further fueled by technological advancements in smart inhalers, supportive regulatory frameworks, and the launch of innovative products by major industry players.

Smart inhalers improve patient adherence by enabling real-time monitoring of medication usage and sending reminders, which can enhance treatment outcomes and better control symptoms. They also generate critical data that supports personalized treatment plans and facilitates the monitoring of disease progression, which is essential for managing chronic lung conditions and promoting better respiratory health.

Further market expansion is expected due to ongoing product development efforts supported by regulatory agencies. For instance, in June 2023, Huma obtained FDA Class II clearance for its Software as a Medical Device (SaMD) platform, which is compatible with various third-party devices, including smart inhalers, thanks to its device-agnostic design.

Additionally, in October 2021, Breathe Suite secured 510(k) clearance from the FDA for its Metered-Dose Inhaler V1, a device that transforms standard inhalers into smart inhalers aimed at aiding asthma and COPD patients.

Altogether, these factors create a favorable environment for significant market growth in North America for smart inhalers over the forecast period.

To know more about why North America is leading the market growth in the smart inhalers market, get a snapshot of the Smart Inhalers Market Outlook 

Smart Inhalers Market Dynamics

The smart inhalers market has experienced rapid growth in recent years, driven by advancements in digital health technologies and the increasing prevalence of respiratory diseases such as asthma and COPD. These devices are equipped with sensors that track patient usage, monitor inhalation technique, and provide feedback to enhance medication adherence. As a result, they are positioned as key tools in improving patient outcomes, minimizing hospitalizations, and reducing healthcare costs associated with respiratory diseases. The integration of mobile apps and cloud-based platforms for real-time data sharing has further enhanced their effectiveness, making them indispensable tools for managing chronic conditions.

The adoption of smart inhalers is also being fueled by the increasing demand for personalized medicine. These inhalers are capable of collecting data on a patient’s medication use, environmental triggers, and symptom severity, allowing healthcare providers to offer more tailored treatment plans. As a result, smart inhalers not only help patients manage their conditions more effectively but also provide valuable insights for physicians, leading to improved clinical decision-making. Moreover, the shift towards remote patient monitoring and telemedicine is accelerating the use of these devices, as they facilitate seamless communication between patients and healthcare professionals.

However, the market for smart inhalers faces certain challenges, including high costs and regulatory hurdles. The initial price of these devices is often higher than traditional inhalers, which can deter widespread adoption, particularly in emerging markets. Additionally, regulatory approval processes for these devices are complex and can delay time-to-market. Manufacturers must navigate varying regulations in different regions, which can complicate product development and distribution. Despite these challenges, the increasing availability of reimbursement models and growing evidence of the cost-effectiveness of smart inhalers are expected to mitigate these issues over time.

The competitive landscape of the smart inhaler market is becoming increasingly dynamic, with both established pharmaceutical companies and startups vying for market share. Partnerships between technology firms and pharmaceutical companies are also becoming more common, as both sides seek to leverage their expertise in digital health and drug delivery systems. In the coming years, the market is expected to see further innovation, with the integration of advanced technologies such as artificial intelligence (AI) for predictive analytics and machine learning models for more precise treatment recommendations. As these technologies continue to evolve, smart inhalers are likely to become an even more integral part of the respiratory healthcare ecosystem.

Get a sneak peek at the smart inhalers market dynamics @ Smart Inhalers COPD Linked to Medical Record 

Smart Inhalers Market Assessment

• Smart Inhalers Market Segmentation
  • Smart Inhalers Market Segmentation By Product Type: Dry Powder Inhaler (DPI) and Metered-Dose Inhaler (MDI)
  • Smart Inhalers Market Segmentation By Device Type: Built-In Smart Inhaler and Attach-Type Smart Inhaler
  • Smart Inhalers Market Segmentation By Indication: Asthma, Chronic Obstructive Pulmonary Disorders [COPD], and Others
  • Smart Inhalers Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the smart inhalers market are set to emerge as the trendsetter explore @ Smart Inhalers Companies 

Table of Contents 

Interested in knowing the smart inhalers market by 2032? Click to get a snapshot of the Bluetooth-enabled Smart Inhalers 

Related Reports

Respiratory Inhalers Market

Respiratory Inhalers Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key respiratory inhalers companies, including Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A., Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd, Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, HONSUN, among others.

Dry Powder Inhaler Devices Market

Dry Powder Inhaler Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key dry powder inhaler devices companies, including Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc, GSK Group of Companies, Hovione, OPKO Health Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd, Radius Innovation & Development, Otsuka Pharmaceutical Co Ltd, RESPIRA THERAPEUTICS INC, MannKind Corporation, Pharmaxis Ltd, Stevanato Group, Harro Höfliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS, among others.

Metered Dose Inhaler Devices Market

Metered Dose Inhaler Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key metered dose inhaler devices companies, including H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc., among others.

Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key COPD companies, including Sanofi, Regeneron Pharmaceuticals, GlaxoSmithKline, AstraZeneca, Amgen, among others.

Asthma Market

Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679 

• Author
• Recent Posts

GlobeNewswire

GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Latest posts by GlobeNewswire (see all)

• Milled Carbon Fiber Market worth $302 million by 2029, at a CAGR of 10.8%, says MarketsandMarkets™ - June 5, 2025
• Logan Ridge Announces Change of Date to the Special Meeting of Stockholders to Allow Additional Time for Stockholders to Vote “FOR” the Merger Proposal - June 5, 2025
• Administrator Loeffler Applauds House Passage of“Save SBA from Sanctuary Cities Act” - June 5, 2025